Navidence, a technology company focused on defining health data and supporting researchers in study design, today announced it has completed its Series Seed preferred funding round, co-led by Grand Ventures (Grand Rapids, Michigan) and Nina Capital (Barcelona, Spain).

The life sciences industry is increasingly embracing ethically obtained health data—commonly referred to as real-world data (RWD)—but determining which data is appropriate for specific research use cases, such as clinical trials, remains a challenge. Manual, fragmented processes continue to slow research teams and create uncertainty.

Making Real-World Data Research-Ready

Founded in 2022, Navidence delivers AI-native technology and professional services that make it significantly easier to design and deploy clinical research studies using RWD. Its platform creates Computable Operational Definitions (CODefs)—standardized definitions of key study elements that are both human- and machine-readable.

These CODefs act as a bridge between clinical healthcare and research, providing the consistency, precision, efficiency, and trust required by regulatory agencies and research stakeholders.

“There’s an enormous opportunity to make real-world data more usable and trustworthy,” said Aaron Kamauu, CEO and co-founder of Navidence. “With this funding, we’re advancing tools that directly reduce burdens on research teams, making the work—from protocol creation to study execution—more efficient and quickly aligning stakeholders throughout the process.”

Solving a Core Challenge in Life Sciences

As RWD plays an increasingly important role in how therapies are developed, evaluated, and regulated, researchers often struggle with fragmented and inconsistent data definitions—the foundational elements of data science.

Navidence addresses this problem through a combination of technology, curated CODef libraries, and expert services. This enables research teams to design studies with greater confidence, objectively selecting fit-for-purpose RWD regardless of source.

“As real-world data becomes increasingly central to drug development and regulatory decision-making, the industry needs more than access to data—it needs clarity, consistency, and trust,” said James Hill, Partner at Grand Ventures. “Navidence is building foundational infrastructure that helps life sciences teams translate complex healthcare data into standardized, computable definitions that can be reused and trusted across studies.”

“Navidence is providing the essential ‘Rosetta Stone’ for real-world data,” added Sebastian Anastassiou, Partner and Head of Investments at Nina Capital. “By bridging the gap between clinical care and rigorous research, they are building the infrastructure needed to make RWD-driven research a global standard.”